Pipeline
Debiopharm’s projects cover all molecule type proteins, peptides, small molecules
Oncology
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ naratuximab emtansine (Debio 1562)
Diffuse large B-cell lymphoma – Anti-CD37 ADC
Anti-CD37 ADC
ODD
_ naratuximab emtansine (Debio 1562M)
Oncology – anti-CD37 ADC/Multilink
anti-CD37 ADC/Multilink
_ Debio 4226
GnRH agonist analogue – 12M Central Precocious Puberty
12M Central Precocious Puberty
_ Debio 4126
Acromegaly – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 4127
Gastroenteropancreatic neuroendocrine tumor – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 4228
Oncology – Undisclosed
Undisclosed
_ Debio 0228
Oncology – CAIX-targeted radiotherapy
CAIX-targeted radiotherapy
_ Debio 4028
Oncology – IAP antagonist
IAP antagonist
Merck
ODD: Orphan Drug Designation
Merck: Merck KGaA
Infectious disease
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ afabicin (Debio 1450)
Bone & joint infections – FabI inhibitor
FabI inhibitor
ODD/FT/QIDP
_ afabicin (Debio 1450)
ABSSSI – FabI inhibitor
FabI inhibitor
FT/QIDP
_ Debio 1453
N. gonorrhoeae – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/S
A. baumannii – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/M
GI disorders – microbiome remodeling
microbiome remodeling
Takeda
_ FibroTrap™ (Debio 1561)
Infectious diseases – Sample prep. Technology
Sample prep. Technology
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X: CARB-X
Takeda: Takeda
Our commercialized products
Clinical trials
Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.